Back to previous section

ImmuPharma can't explain near-400% stock jump

Specialist drug discovery and development outfit ImmuPharma has said that it can't pinpoint a reason behind its share price more than quadrapling over the past month.

  • Immupharma
  • 28 January 2025 13:40:53
ImmuPharma

Source: Sharecast

As announced to the market on 9 January, the company said it had made "innovative groundbreaking advancements" in its preclinical research program focused on P140, an active peptide against the autoimmune disease, Lupus SLE.

While it didn't release any data at the time, ImmuPharma said that its findings were paving the way for earlier and more accurate diagnostics, as well as identifying patients most likely to respond to P140 therapy and improving the monitoring of patients' response to the treatment.

Since that announcement, the stock has rocketed more than 380% to the 5.6p mark, trading at levels not seen since September 2022.

In recent weeks, the company said it had also attended the JP Morgan and Biotech Showcase healthcare conferences, where it had "positive discussions with a number of global biopharma companies".

In a statement on Tuesday, the firm said: "ImmuPharma is not aware of any further material commercial or operational reason for the significant share price movements, however, the company will continue to update the market on developments, both commercially and scientifically, when appropriate, over the next period."

N/A

Isin: N/A
Exchange: N/A
Sell:
N/A
Buy:
N/A
Change:
Date:
Prices delayed by at least 15 minutes

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

View our accounts

Lloyds Bank is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.

Important legal information

Lloyds and Lloyds Bank are trading names of Halifax Share Dealing Limited. The Lloyds Bank Direct Investments Service is operated by Halifax Share Dealing Limited. Registered Office: Trinity Road, Halifax, West Yorkshire, HX1 2RG. Registered in England and Wales no. 3195646. Halifax Share Dealing Limited is authorised and regulated by the Financial Conduct Authority, 12 Endeavour Square, London, E20 1JN under registration number 183332. A Member of the London Stock Exchange and an HM Revenue & Customs Approved ISA Manager.

Logo Allfunds

The information contained within this website is provided by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd unless otherwise stated. The information is not intended to be advice or a recommendation to buy, sell or hold any of the shares, companies or investment vehicles mentioned, nor is it information meant to be a research recommendation. This is a solution powered by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd incorporating their prices, data news, charts, fundamentals and investor tools on this site. Terms and conditions apply. Prices and trades are provided by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd and are delayed by at least 15 minutes.

FE fundinfo Logo

Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.

Refinitiv Logo

© 2025 Refinitiv, an LSEG business. All rights reserved.